問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Link to Hospital

  • 2,634

    Total Beds

  • 1,095

    Total Doctors

  • jmventcc@cgmh.org.tw
  • CHANG-CHIEN, CHIA-MIN
  • 07-7317123#6416
  • 833Kaohsiung CityKaohsiung NiaosongNo. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833 , Taiwan (R.O.C.)

Recruiting Trial

554Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1389Cases

2025-10-01 - 2032-01-31

Phase II/III

Active
A phase 2/3, open-label, randomized trial evaluating the efficacy of telisotuzumab adizutecan monotherapy versus osimertinib in patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who have progressed after third-generation EGFR TKI therapy, compared with standard of care. - AndroMETa-Lung-713

  • Condition/Disease

    Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
8Sites

Recruiting8Sites

2025-09-23 - 2028-02-13

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    Film-coated tablets Film-coated tablets

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Injectable drugs Subcutaneous injections Injectable drugs Injectable drugs Injectable drugs

Participate Sites
7Sites

Recruiting7Sites

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    Capsules Intravenous Infusion Intravenous Infusion Capsules

Participate Sites
7Sites

Recruiting7Sites

2025-10-31 - 2029-06-26

Not yet recruiting
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

  • Condition/Disease

    Moderate to severe chronic obstructive pulmonary disease (COPD)

  • Test Drug

    UPB-101

Participate Sites
8Sites

Not yet recruiting8Sites

2025-10-01 - 2029-03-27

Others

Not yet recruiting
A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Injectable

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

  • Condition/Disease

    Focal Segmental Glomerulosclerosis

  • Test Drug

    Film-coated tablets Film-coated tablets

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2030-06-07

Others

Active
A phase 3b/4, multicenter, randomized, open-label, long-term safety trial comparing deucravacitinib with ustekinumab in participants with moderate to severe plaque psoriasis (PRAGMATYK).

  • Condition/Disease

    Participants with moderate to severe plaque psoriasis (PRAGMATYK)

  • Test Drug

    Shu Ting Coated Tablets 6 mg

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2025-11-01 - 2027-10-11

Phase I/II

Not yet recruiting
A randomized, double-blind, phase 1/2a trial was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DB-2304 injection in healthy adult participants and participants with systemic lupus erythematosus or cutaneous lupus erythematosus.

  • Condition/Disease

    Systemic lupus erythematosus

  • Test Drug

    DB-2304

Participate Sites
4Sites

Recruiting4Sites

2025-11-14 - 2030-06-28

Phase III

Active
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Investigate the Efficacy, Safety, and PK/ PD of Finerenone, in Addition to Standard-of-care, in Pediatric Patients, 6 Months to < 18 Years of Age With Heart Failure (HF) and Left Ventricular Systolic Dysfunction (LVSD)

  • Condition/Disease

    Left Ventricular Systolic Dysfunction

  • Test Drug

    Tablets Tablets Tablets Granules for suspension Tablets Granules for suspension

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 139
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB